Topical IL-1-Ra for Treatment of Corneal Neovascularization

• Status: Terminated
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts Eye and Ear Infirmary; Reza Dana, MD
• Treatments: Interleukin 1 Receptor Antagonist Protein

Criteria

Inclusion Criteria:

• Ability to provide written informed consent and comply with study assessments for the full duration of the study

• Age > 18 years

• Patients with superficial or deep corneal NV that extends farther than 1 mm from the limbus

• Patients are in generally good stable overall healthExclusion Criteria: • Has received treatment with anti-VEGF agents (topical, intraocular or systemic) within 30 days of study entry

• Corneal or ocular surface infection within 30 days prior to study entry• Ocular or periocular malignancy

• Contact lens (excluding bandage contact lens) use within 2 weeks prior to study entry

• Persistent epithelial defect (>1mm and ≥14 days duration) within 2 weeks prior to study entry

• Intravitreal or periocular steroids within 2 weeks prior to study entry

• Change in dose/frequency of topical steroids and/or NSAIDs within 2 weeks prior to study entry

• Pregnancy (positive pregnancy test) or lactation

• Premenopausal women not using contraception

• Signs of current infection, including fever and current treatment with antibiotics

• Participation in another simultaneous medical investigation or trial